secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001193125-23-176725
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics shareholders reject share increase, approve reverse split at 2023 annual meeting
--------------------------------------------------------------------------------

- Dennis Berman and Gisele Dion elected as Class III directors with 16.3M and 16.7M votes for, respectively.
- Proposal to increase authorized shares from 100M to 200M failed (20.6M for, 2.2M against; not enough votes).
- Approved reverse stock split authorization (1-for-5 to 1-for-20) with 21.9M votes.
- Proposal to eliminate supermajority vote requirement for charter amendments failed (15.5M for, 6.1M broker non-votes).
- Ratification of CohnReznick as auditor passed with 22.8M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/0001193125-23-176725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/d518755d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-176725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer